Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Biogen stock rises on upgrade ahead of key Alzheimer’s drug Phase 2 study data release
BIIB
$207.70
+$8.55 +4.29%

Biogen stock rises on upgrade ahead of key Alzheimer’s drug Phase 2 study data release

Analyst Insights
13 Jul 2026
Barrons
View Source
Bullish
pluang ai news

Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheimer's treatment and Biogen's market position. The company is set to reveal these results soon, which has generated optimism among Wall Street analysts.

More News (BIIB)

New data shows subcutaneous LEQEMBI matches IV efficacy for early Alzheimer's, offering easier dosing.

New data shows subcutaneous LEQEMBI matches IV efficacy for early Alzheimer's, offering easier dosing.

Eisai and Biogen presented data at AAIC 2026 showing that LEQEMBI's subcutaneous autoinjector delivers similar efficacy and safety to intravenous administration for early Alzheimer's disease. The once-weekly 500 mg subcutaneous dose achieves comparab...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App